2022
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification
Trapani D, Franzoi M, Burstein H, Carey L, Delaloge S, Harbeck N, Hayes D, Kalinsky K, Pusztai L, Regan M, Sestak I, Spanic T, Sparano J, Jezdic S, Cherny N, Curigliano G, Andre F. Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Annals Of Oncology 2022, 33: 702-712. PMID: 35550723, DOI: 10.1016/j.annonc.2022.03.273.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicHumansMedical OncologyNeoplasmsProspective StudiesQuality of LifeRetrospective StudiesConceptsNon-inferiority clinical trialClinical trialsESMO classificationCancer treatmentPrecision Medicine Working GroupSingle-arm studyHealth system burdenOngoing clinical trialsShorter treatment durationLevel of evidenceEvidence-based criteriaQuality of lifePublic health expertsMedicine Working GroupStandard regimensCohort investigationWorking GroupCumulative doseTreatment modalitiesTreatment modulationPatient representativesTreatment durationIntermittent scheduleFinancial toxicityEvidence of reduction
2021
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology
Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, Tjan-Heijnen V, Martin M, Rottey S, Generali D, Campone M, Cristofanilli M, Pusztai L, Peeters M, Berchem G, Cortes J, Ruhstaller T, Ciruelos E, Rugo HS, Jerusalem G. Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO Global Oncology 2021, 7: go.20.00589. PMID: 33529077, PMCID: PMC8081548, DOI: 10.1200/go.20.00589.Peer-Reviewed Original ResearchConceptsMedical oncologistsCOVID-19 positive patientsCOVID-19 outbreakUse of telemedicineClinical trial activityAffected modalityPalliative treatmentOncology unitLong-term impactNational registryPostacute phaseClinical activityMultidisciplinary meetingOncologic activityLocal registryHealthcare staffTreatment adaptationPatientsEarly cessationTrial activityHealthcare systemCOVID-19 pandemicOncologistsRegistrySignificant reduction
2018
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard J, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals Of Oncology 2018, 29: 1895-1902. PMID: 30137196, PMCID: PMC6158764, DOI: 10.1093/annonc/mdy263.Peer-Reviewed Original ResearchConceptsESMO ScaleMolecular targetsClinical actionabilityPrecision Medicine Working GroupGenomic alterationsPrecision medicineRoutine clinical decisionEvidence-based criteriaMedicine Working GroupLack of evidencePreclinical evidenceClinical benefitClinical evidencePatient populationClassification systemClinical managementCancer precision medicineInvestigational targetsPatient managementMolecular aberrationsTumor typesClinical decisionClinical targetsAvailable evidenceEuropean Society
2016
Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach
Safonov A, Wang S, Gross CP, Agarwal D, Bianchini G, Pusztai L, Hatzis C. Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. Breast Cancer Research And Treatment 2016, 155: 223-234. PMID: 26749360, PMCID: PMC5990969, DOI: 10.1007/s10549-016-3677-3.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCost-effectiveness analysisPredictive biomarkersBiomarker-guided treatmentIncremental cost-effectiveness ratioHealth-related qualityTreatment costsCost-effectiveness ratioClinical outcomesClinical efficacyPrognostic biomarkerTraditional cost-effectiveness analysisBiomarker useLife yearsBiomarker valuesBiomarker prevalenceClinical literatureBiomarkersTreatmentState transition modelDecision analytic approachMedical utilityDecision analytic toolsCrizotinibHER2
2005
Oncogenomics 2005--Dissecting Cancer through Genome Research. 2-6 February 2005, San Diego, CA, USA.
Pusztai L. Oncogenomics 2005--Dissecting Cancer through Genome Research. 2-6 February 2005, San Diego, CA, USA. IDrugs 2005, 8: 215-8. PMID: 15772892.Peer-Reviewed Original ResearchGene expression profiling of primary breast cancer
Rouzier R, Wagner P, Morandi P, Pusztai L. Gene expression profiling of primary breast cancer. Current Oncology Reports 2005, 7: 38-44. PMID: 15610685, DOI: 10.1007/s11912-005-0024-y.Peer-Reviewed Original Research